Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Glenda Gray, program director of a research consortium, talked with STAT about the impact of the funding freeze on an HIV ...

A groundbreaking project to study potential HIV vaccines in several African countries has been derailed by an abrupt cut in funding from the United States government. As a result, several promising ...

A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...

Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But ...

Protein crystallization at the SER-CAT beamline at Argonne’s Advanced Photon Source proved key to the discovery of a new HIV vaccine candidate.

This research on a T-cell–targeting vaccines in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of ...

An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...